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The off-label use of drugs in oncology:
a position paper by the European Society
for Medical Oncology (ESMO)
All drugs need to be given a marketing authorization by
a relevant regulatory body in order for patients to receive them
[1]. The marketing authorization is granted if the drug is
judged to be safe and effective for a given indication following
a given administration regimen. This is the drug ‘label’. When
the drug is used for other indications, it is used ‘off label’.
This is different from when a drug is ‘unlicensed’. In this
case, the drug is not accessible on the market, and, in principle,
its use can take place only within clinical studies, or
a compassionate/expanded access setting, generally being
provided for free by the pharmaceutical company.
The off-label use of drugs in oncology has been estimated to
reach 50%, or even more [2–4]. In pediatrics, the off-label issue
is particularly widespread, all the more in pediatric oncology
[5]. Often, these uses of drugs, although off-label, are fully
‘evidence based’, and therefore fall within the state of the art. In
spite of this, off-label uses of drugs might be viewed as illegal, in
a sense. In practice, off-label uses are often ‘tolerated’ under
restrictions, in spite of the size of the phenomenon, especially
in some medical areas.
In principle, a drug can be off label under three conditions:
(i) because steps to extend the approval have not been made,
although evidence of efficacy is available; (ii) because it falls
into the so-called ‘gray zone’ of evidence-based medicine,
within which high-level evidence is difficult to reach even for
treatments which are likely effective (this may be the case of
rare diseases, which do not lend themselves to large clinical
studies) and (iii) because the drug is ineffective or at least there
is no reason to believe it is effective. Obviously, the off-label
issue is of the greatest concern under the first condition, and
constitutes a problem under the second, while ineffective
treatments simply should not be done.
The off-label issue is more acute in oncology than in other
medical areas for some reasons. The main one is the number of
cancer types. In fact, each anticancer drug may be useful in
several of them. In practice, many widespread anticancer drugs
have not got the label for all the indications under which they
can be effectively employed. When the drug patent is over, no
pharmaceutical company will ever have any interest to pursue
any label extension. Rare entities are all the more problematic.
With regard to these, benefits are granted to pharmaceutical
companies seeking the approval of new drugs for rare diseases,
the so-called ‘orphan drugs’: in essence, economic incentives are
guaranteed if the drug is approved [6]. Several anticancer agents
are now obtaining the approval as orphan drugs. The
mechanism, however, is not a guarantee at all, and in any case
applies only to rare diseases. In general, the more specific the
label is, the more likely some minor indications may remain
uncovered, and this can well occur also if the disease is frequent.
In the end, there is a problem in principle that the
approval of a new drug can be sought exclusively by the
pharmaceutical company which produces it. If the
pharmaceutical company does not have enough interest to
pursue the approval on a specific indication, this will be left
uncovered, and the use of the drug for such an indication will
be off label. The wide diversity of clinical practice adds to this,
creating the above-mentioned gray zone of evidence-based
medicine [7]. The paradox is that clinical practice guidelines
often recommend to use drugs off label, thus outside existing
regulatory boundaries, ‘against’ the law, in a sense. In theory,
the reverse should take place: regulatory boundaries should
be wider, and clinical practice guidelines should be selective
within them.
The off-label issue continuously creates problems to clinical
practice, and at intervals may become more acute in one
country or another. According to its Bylaws, European Society
for Medical Oncology (ESMO) is dedicated ‘to promote equal
access to optimal cancer care of all cancer patients’ [8]. As
stated recently by American Society of Clinical Oncology
(ASCO) and ESMO, ‘health care plans should aspire to meet
certain common goals to ensure access to, and the continuity
of, quality cancer care’ [9]. In regard to the off-label uses of
drugs, ESMO believes:
 that the problem of off-label uses of drugs should be urgently
addressed and solved positively, when such uses are
supported by evidence and amount to standard practice;
 that regulatory bodies should take some responsibility on the
off-label issue;
 that, pragmatically, lists of drugs with acceptable indications
should be worked out in order to remove them from the off-
label area, and in the European Union (EU) this might follow
the principle underlying the centralized procedure for
approval of new drugs, thus possibly involving the EU
regulatory body, the European Medicines Agency (EMEA);
 that, in perspective, new regulatory mechanisms should be
searched, by which uses of drugs could be expanded even beyond
the initiative of pharmaceutical companies producing them.
The problem needs to be urgently addressed
The persisting need to use drugs off-label constitutes a serious
concern. In fact, by prescribing a drug off-label, the physician is
asked to take a special responsibility. Formally, he is prescribing
something which the regulatory body has not stated is safe and
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effective. Therefore, he/she may be called to respond for any
problem arising from the use of the drug as if he/she had done
something outside the state of the art. Often this is not the case,
but the burden of the proof rests on the physician. In any case,
the responsibility can be administrative, and third payers may
claim that the prescription was not allowed, so that the
physician may even be called to reimburse personally or be
threatened to do so. Indeed, this may be actually foreseen,
although it is often left to the discretion of ‘watchdogs’ to
decide how much to pursue controls. At the very least,
physicians may be facing more red tape in order to prescribe
off-label drugs. All this can discourage evidence-based
prescriptions of off-label drugs. More simply, third payers,
whether public (national health systems, and the like) or
private, might just refuse to reimburse some off-label drugs, at
their discretion. In other words, there is room for improper
denials of effective therapies, in an age of mounting health costs
constraints. Overall, this might add to existing inequalities in
treatment [3, 4, 10].
Regulatory bodies should take responsibility
Regulatory bodies often argue that reimbursing off-label
drugs or not is exclusively a matter of third payers. The
argument is tenable to some extent, but nonetheless is weak if it
implies that regulatory bodies are completely out of the story.
The first reason is that, as said above, the implications of the
off-label use of drugs are not only financial, but also affect
physicians’ professional responsibility. Another reason is that
third payers, in principle, should ‘buy’ drugs only from among
on-label ones. This is exactly why regulatory bodies do exist: to
allow patients and their proxies to find safe and effective drugs
on the market. As was said, a ‘general off-label use of drugs is
the death of the idea of regulation’ [11]. Indeed, it is well
accepted that regulatory bodies take some responsibility to
ensure that effective drugs get to the market even when there
are obstacles (thus, for instance, the provisions about orphan
drugs). A different argument at the EU level is that these are
internal matters of individual states. In the EU, however,
anticancer drugs are now subjected to the centralized procedure
for marketing authorization of medicinal products, by which
the EU regulatory body, EMEA, is responsible for evaluating
all the applications, which are centrally made by companies and
whose outcomes are relevant for all the EU states [12].
Therefore, the principle of central responsibility for
anticancer drugs by the regulatory body, EMEA, is well
established in the EU.
Lists of acceptable drugs should be worked out
Pragmatically, tools which make it possible for some patients to
receive off-label drugs are in place in some countries, in an
effort to overcome a limitation which in the end is only
bureaucratic. These tools may well include lists of drugs
accepted for selected indications, outside those recognized in
the labels, as a very practical way to let patients receive what
they need for. In 2006, the ASCO stressed the need to update
and fully implement the ‘standard medical compendia’ used by
Medicare in the United States to cover selected, evidence-based,
off-label uses of anticancer drugs [2]. As they stated, ‘working
closely with the cancer community, Congress has fashioned
a strong system for identifying medically appropriate cancer
therapies, including those that involve off-label uses of United
States Food and Drug Administration approved drugs. The
system has worked well, as reflected in improvement of cancer
morbidity and mortality’ [2]. In Europe, states have different
policies in regard to the off-label issue, which are often unclear
and liable to lead to improper denials. ESMO is carrying out
a survey of such policies. There is an obvious need to improve
and assimilate them. A powerful solution would be that the EU
regulatory body might facilitate the production of compendia
of anticancer drugs, enlisting those off-label uses judged to be
legitimate.
The initiative of seeking label extensions, or the
mechanisms to expand drugs uses, should not
depend exclusively on pharmaceutical companies
Medicines for human use are common goods. A high level of
social responsibility is implied. A pharmaceutical company
may, however, not be willing to pursue label extensions for
some of its drugs. Efforts such as those on orphan drugs are to
be warmly appreciated, but they may not be enough, since in
the end the decision is left to the company, and, furthermore,
rare tumors are not the only problem. On the other hand,
approving a label extension may not be as demanding as
approving a drug for its first indication, first of all in regard to
safety. Therefore, while obviously it is only up to the
pharmaceutical company to decide whether to bring a new
agent onto the market or not, extending an existing label might
well follow different rules [11]. Why communities of
researchers, the academy, advocacy groups and professional/
scientific societies should not have any say in all this in
cooperation with the regulatory bodies?
In conclusion, at a time when health expense constraints may
easily lead to inequalities in patients’ access to available
appropriate care, ESMO advocates concrete political steps
about the off-label uses of anticancer drugs. Likewise, ESMO
wants to support medical oncologists who in this regard find
themselves before health administrators or third payers in the
need to assert some essential principles of good quality of care.
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